Quantcast

Latest Cancer immunotherapy Stories

2014-06-05 08:28:41

In vivo T cell active immunotherapy generated from DCVex(TM) platform SEATTLE and SOUTH SAN FRANCISCO, Calif., June 5, 2014 /PRNewswire/ -- Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced treatment of the first patient in a Phase 1 clinical trial of LV305, an immuno-oncology investigational agent from the company's DCVex(TM) lentiviral vector platform....

2014-06-04 12:28:56

TUCSON, Ariz., June 4, 2014 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group and MedImmune, the global biologics research and development arm of AstraZeneca, today announced they are jointly developing a PD-L1 (SP263) immunohistochemistry assay to enroll patients in clinical trials for MedImmune's MEDI4736 anti-PD-L1 therapy for non-small cell lung carcinoma. This includes the recently commenced MEDI4736 ATLANTIC trial that will enroll only...

2014-06-03 12:36:41

ImaginAb Expands Portfolio for Immunotherapeutic Drug Development LOS ANGELES, June 3, 2014 /PRNewswire/ -- ImaginAb, Inc. and the Regents of the University of California, Los Angeles (UCLA) have executed a technology licensing agreement relating to novel immune cell-targeting agents for imaging with Positron Emission Tomography (PET). Inflammation and immune response play a fundamental role in a wide variety of diseases including cancer and autoimmune diseases. Under the agreement,...

2014-06-01 08:20:41

NEW YORK, June 1, 2014 /PRNewswire/ -- The Cancer Research Institute (CRI) is proud to announce the launch of a first-of-its-kind website devoted to cancer immunotherapy, also called immuno-oncology, designed specifically for cancer patients and their caregivers, TheAnswerToCancer.org. http://photos.prnewswire.com/prnvar/20140530/92827 "As major advances in cancer immunotherapy begin to alter the landscape of cancer treatment, patients facing a cancer diagnosis need to be aware of...

2014-06-01 08:20:34

NKTR-214 combined with anti-PD-1 or anti-CTLA-4 provides significant tumor growth inhibition in both EMT6 breast and CT26 colon tumor models SAN FRANCISCO, June 1, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced positive preclinical data for NKTR-214, a new investigational cancer immunotherapy which selectively activates the IL-2 receptor complex and is being developed as a potential treatment for multiple cancers. The results were presented today at the 2014 ASCO...

2014-05-30 08:25:21

SANTA MONICA, Calif., May 30, 2014 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced the Company will provide details on key features of the rapid, 6-day manufacturing process that is expected to underlie its most advanced personalized cancer immunotherapy program. The technology is expected to underpin a Kite clinical trial in...

2014-05-29 12:29:19

PRINCETON, N.J., May 29, 2014 /PRNewswire/ -- inVentiv Health Clinical, a leading global clinical research organization (CRO), and Advaxis, Inc. (NASDAQ: ADXS), a biotechnology company developing cancer immunotherapies, announced today that they have entered into a global master services agreement for the clinical development of certain immunotherapy product candidates in Advaxis's proprietary pipeline. inVentiv initially will work with Advaxis to develop clinical study protocols and will...

2014-05-28 16:26:55

Educational and Awareness Raising Events Scheduled throughout the Month of June NEW YORK, May 28, 2014 /PRNewswire/ -- The Cancer Research Institute (CRI) is pleased to host its second annual Cancer Immunotherapy Month in June, aimed at increasing awareness of cancer immunotherapy, also known as immuno-oncology, a class of cancer treatment that mobilizes the immune system to fight the disease. Immunotherapy was named Science magazine's 2013 Breakthrough of the Year, and is anticipated once...

2014-05-28 08:31:36

-- Ongoing Phase 1 Cancer Immunotherapy Study to be Presented at the Annual Meeting of the American Society of Clinical Oncology -- REDWOOD CITY, Calif., May 28, 2014 /PRNewswire/ -- ARMO BioSciences, Inc., a clinical-stage biotechnology company, today announced it raised $30 million in a Series B private financing led by NanoDimension. Existing investors Kleiner Perkins Caufield & Byers, OrbiMed and DAG Ventures also participated in the round. "This financing validates both...

2014-05-27 12:32:22

SEATTLE, May 27, 2014 /PRNewswire/ -- Adaptive Biotechnologies, the pioneer of Next Generation Sequencing of the adaptive immune system, and its collaborators will present data supporting the clinical application of immunosequencing in diagnosing and monitoring T cell lymphomas at the 2014 Annual Meeting of the American Society of Clinical Oncology. Data will also be presented demonstrating how immunosequencing can be used to elucidate the activity of immunotherapeutic combination...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related